<?xml version="1.0" encoding="UTF-8"?>
<CustomObjectTranslation xmlns="http://soap.sforce.com/2006/04/metadata">
    <caseValues>
        <plural>false</plural>
        <value>Connaissances médicales sur le terrain</value>
    </caseValues>
    <caseValues>
        <plural>true</plural>
        <value>Connaissances médicales sur le terrain</value>
    </caseValues>
    <fields>
        <label>Aligné sur connaissance clé (TROUSSE)</label>
        <name>Aligned_to_Key_Insight_Topic_KIT_BMS_IC__c</name>
        <picklistValues>
            <masterLabel>AR antagonist (prostate cancer)</masterLabel>
            <translation><!-- AR antagonist (prostate cancer) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>ASENAPINE</masterLabel>
            <translation><!-- ASENAPINE --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Adjuvant Melanoma Landscape/Treatment Paradigms</masterLabel>
            <translation><!-- Adjuvant Melanoma Landscape/Treatment Paradigms --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Advanced Melanoma Landscape/Treatment Paradigms</masterLabel>
            <translation><!-- Advanced Melanoma Landscape/Treatment Paradigms --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Algorithm placement</masterLabel>
            <translation><!-- Algorithm placement --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Anticoagulation therapy in AF</masterLabel>
            <translation><!-- Anticoagulation therapy in AF --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Apixaban</masterLabel>
            <translation><!-- Apixaban --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>BMS Concerns</masterLabel>
            <translation><!-- BMS Concerns --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Biomarkers</masterLabel>
            <translation><!-- Biomarkers --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Biomarkers &amp; Diagnostics</masterLabel>
            <translation><!-- Biomarkers &amp; Diagnostics --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Biomarkers of depression</masterLabel>
            <translation><!-- Biomarkers of depression --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Bipolar Maintenance Trials</masterLabel>
            <translation><!-- Bipolar Maintenance Trials --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Brivanib alaninate (VEGFR/FGFR inhibitor) (solid tumors: HCC, CRC)</masterLabel>
            <translation><!-- Brivanib alaninate (VEGFR/FGFR inhibitor) (solid tumors: HCC, CRC) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CARIPRAZINE</masterLabel>
            <translation><!-- CARIPRAZINE --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CML Landscape/Treatment Paradigms</masterLabel>
            <translation><!-- CML Landscape/Treatment Paradigms --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>COMPETITOR ACTIVITY</masterLabel>
            <translation><!-- COMPETITOR ACTIVITY --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CV outcomes and LCM studies w. DPP-4is and GLP-1s</masterLabel>
            <translation><!-- CV outcomes and LCM studies w. DPP-4is and GLP-1s --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Clinical trials (information on)</masterLabel>
            <translation><!-- Clinical trials (information on) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Competitive Intelligence</masterLabel>
            <translation><!-- Competitive Intelligence --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Competitors (Factor Xa Inhibitors and DTIs) in AF</masterLabel>
            <translation><!-- Competitors (Factor Xa Inhibitors and DTIs) in AF --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Current Products</masterLabel>
            <translation><!-- Current Products --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>DISEASE STATE/SPECIAL POPULATIONS</masterLabel>
            <translation><!-- DISEASE STATE/SPECIAL POPULATIONS --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>DSM 5</masterLabel>
            <translation><!-- DSM 5 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Darunavir</masterLabel>
            <translation><!-- Darunavir --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Depression landscape</masterLabel>
            <translation><!-- Depression landscape --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Dolutegravir</masterLabel>
            <translation><!-- Dolutegravir --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Dopamine As A Unique Target</masterLabel>
            <translation><!-- Dopamine As A Unique Target --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Education</masterLabel>
            <translation><!-- Education --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Education and Awareness</masterLabel>
            <translation><!-- Education and Awareness --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Efficacy</masterLabel>
            <translation><!-- Efficacy --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>ErbB/VEGF receptor inhibitor (solid tumors)</masterLabel>
            <translation><!-- ErbB/VEGF receptor inhibitor (solid tumors) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>FDC</masterLabel>
            <translation><!-- FDC --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>For MORAb-003 (Phase II, Morphotek):</masterLabel>
            <translation><!-- For MORAb-003 (Phase II, Morphotek): --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Future DPP4-I launches</masterLabel>
            <translation><!-- Future DPP4-I launches --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Future Products/Indications</masterLabel>
            <translation><!-- Future Products/Indications --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>GLP-1 Agonists</masterLabel>
            <translation><!-- GLP-1 Agonists --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Gastric Landscape/Treatment Paradigms</masterLabel>
            <translation><!-- Gastric Landscape/Treatment Paradigms --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Guidelines/algorithms/position statements</masterLabel>
            <translation><!-- Guidelines/algorithms/position statements --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>IGF-1R antagonist (solid tumors)</masterLabel>
            <translation><!-- IGF-1R antagonist (solid tumors) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>IL-6</masterLabel>
            <translation><!-- IL-6 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Impact of Cost and Treatment Pathways (specify Tumor type if known)</masterLabel>
            <translation><!-- Impact of Cost and Treatment Pathways (specify Tumor type if known) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Impact of cost and Treatment Pathways</masterLabel>
            <translation><!-- Impact of cost and Treatment Pathways --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Ipilimumab (CTLA-4 receptor antagonist) (melanoma)</masterLabel>
            <translation><!-- Ipilimumab (CTLA-4 receptor antagonist) (melanoma) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Ixabepilone (tubulin polymerization) (solid tumors)</masterLabel>
            <translation><!-- Ixabepilone (tubulin polymerization) (solid tumors) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Januvia Medical Strategy</masterLabel>
            <translation><!-- Januvia Medical Strategy --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>LURASIDONE</masterLabel>
            <translation><!-- LURASIDONE --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>MDD:  General</masterLabel>
            <translation><!-- MDD:  General --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>MOA</masterLabel>
            <translation><!-- MOA --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>MOA (ALL)</masterLabel>
            <translation><!-- MOA (ALL) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Managed Markets/Patient Assistance</masterLabel>
            <translation><!-- Managed Markets/Patient Assistance --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Medical Questions</masterLabel>
            <translation><!-- Medical Questions --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Met kinase inhibitor (solid tumors)</masterLabel>
            <translation><!-- Met kinase inhibitor (solid tumors) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Mutations</masterLabel>
            <translation><!-- Mutations --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>NSCLC Landscape/Treatment Paradigms</masterLabel>
            <translation><!-- NSCLC Landscape/Treatment Paradigms --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>NSCLC and SCLC Landscape/Treatment Paradigms</masterLabel>
            <translation><!-- NSCLC and SCLC Landscape/Treatment Paradigms --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Neuroimaging</masterLabel>
            <translation><!-- Neuroimaging --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Novel RA Trial Design (other H2H/VERA/Remission induction/retention studies, etc.)</masterLabel>
            <translation><!-- Novel RA Trial Design (other H2H/VERA/Remission induction/retention studies, etc.) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Other (Please Specify)</masterLabel>
            <translation><!-- Other (Please Specify) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Other Small Molecule compounds for RA (e.g. JAK, Syk, CCR1, BTK, etc.)</masterLabel>
            <translation><!-- Other Small Molecule compounds for RA (e.g. JAK, Syk, CCR1, BTK, etc.) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Outcomes research</masterLabel>
            <translation><!-- Outcomes research --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Ovarian Landscape/Treatment Paradigms</masterLabel>
            <translation><!-- Ovarian Landscape/Treatment Paradigms --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>PAYER LANDSCAPE</masterLabel>
            <translation><!-- PAYER LANDSCAPE --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>PEDIATRICS: General</masterLabel>
            <translation><!-- PEDIATRICS: General --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Patient Flow</masterLabel>
            <translation><!-- Patient Flow --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Patient type</masterLabel>
            <translation><!-- Patient type --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Payer Strategy</masterLabel>
            <translation><!-- Payer Strategy --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Payor</masterLabel>
            <translation><!-- Payor --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Positive Charge</masterLabel>
            <translation><!-- Positive Charge --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>QUETIAPINE XR</masterLabel>
            <translation><!-- QUETIAPINE XR --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Quad</masterLabel>
            <translation><!-- Quad --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>REMS</masterLabel>
            <translation><!-- REMS --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Raltegavir</masterLabel>
            <translation><!-- Raltegavir --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Regulatory and Patent Issues</masterLabel>
            <translation><!-- Regulatory and Patent Issues --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Research Interest</masterLabel>
            <translation><!-- Research Interest --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Revised APA Guidelines for MDD</masterLabel>
            <translation><!-- Revised APA Guidelines for MDD --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Rilpivirine/Complera</masterLabel>
            <translation><!-- Rilpivirine/Complera --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>SCCHN Landscape/Treatment Paradigms</masterLabel>
            <translation><!-- SCCHN Landscape/Treatment Paradigms --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Safety</masterLabel>
            <translation><!-- Safety --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Safety concerns and management strategies</masterLabel>
            <translation><!-- Safety concerns and management strategies --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Specific Competitors</masterLabel>
            <translation><!-- Specific Competitors --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Stakeholders Insights</masterLabel>
            <translation><!-- Stakeholders Insights --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>TENOFOVIR</masterLabel>
            <translation><!-- TENOFOVIR --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Trial design</masterLabel>
            <translation><!-- Trial design --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Trial information, competitor information, etc</masterLabel>
            <translation><!-- Trial information, competitor information, etc --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>anti CD-137 (melanoma, RCC)</masterLabel>
            <translation><!-- anti CD-137 (melanoma, RCC) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>epothilone folate (solid tumors)</masterLabel>
            <translation><!-- epothilone folate (solid tumors) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>fostamatinib (Syk inhibitor)</masterLabel>
            <translation><!-- fostamatinib (Syk inhibitor) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>mCRC Landscape/Treatment Paradigms</masterLabel>
            <translation><!-- mCRC Landscape/Treatment Paradigms --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>mCRPC Landscape/Treatment Paradigms</masterLabel>
            <translation><!-- mCRPC Landscape/Treatment Paradigms --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>tofacitinib/tasocitinib (JAK-3) Pfizer</masterLabel>
            <translation><!-- tofacitinib/tasocitinib (JAK-3) Pfizer --></translation>
        </picklistValues>
    </fields>
    <fields>
        <label><!-- Competitor Product --></label>
        <name>Competitor_Product_BMS_EMEA__c</name>
    </fields>
    <fields>
        <label>Pays</label>
        <name>Country_BMS_IC__c</name>
    </fields>
    <fields>
        <label><!-- Exploratory Development Compound --></label>
        <name>Exploratory_Development_Compound_BMS__c</name>
        <picklistValues>
            <masterLabel>11βHSD Inhibitors (Diabetes)</masterLabel>
            <translation><!-- 11βHSD Inhibitors (Diabetes) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Alpha-7 Nicotinic agonist (pain)</masterLabel>
            <translation><!-- Alpha-7 Nicotinic agonist (pain) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Alpha-7 Nicotonic/mGluR5 PAM (cog/neg symptoms)</masterLabel>
            <translation><!-- Alpha-7 Nicotonic/mGluR5 PAM (cog/neg symptoms) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Anti-CD137 Antibody (Cancer)</masterLabel>
            <translation><!-- Anti-CD137 Antibody (Cancer) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Anti-CXCR4 mAb</masterLabel>
            <translation><!-- Anti-CXCR4 mAb --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Anti-KIR mAb</masterLabel>
            <translation><!-- Anti-KIR mAb --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Anti-PD-L1 mAb</masterLabel>
            <translation><!-- Anti-PD-L1 mAb --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CB1 Antagonist (Obesity)</masterLabel>
            <translation><!-- CB1 Antagonist (Obesity) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CCR2 Antagonist (CV/Met)</masterLabel>
            <translation><!-- CCR2 Antagonist (CV/Met) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CGRP antagonist (migraine)</masterLabel>
            <translation><!-- CGRP antagonist (migraine) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>DGAT Inhibitors (CV / Met)</masterLabel>
            <translation><!-- DGAT Inhibitors (CV / Met) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>DPP4 Inhibitor (Diabetes)</masterLabel>
            <translation><!-- DPP4 Inhibitor (Diabetes) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Delta PKC Inhibitor (Cardiovascular)</masterLabel>
            <translation><!-- Delta PKC Inhibitor (Cardiovascular) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>GABA-nicotinic mod (pain)</masterLabel>
            <translation><!-- GABA-nicotinic mod (pain) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>GR Agonists (Immunology)</masterLabel>
            <translation><!-- GR Agonists (Immunology) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Gamma/MT Stabilizer/Abeta mod (Alzheimer&apos;s)</masterLabel>
            <translation><!-- Gamma/MT Stabilizer/Abeta mod (Alzheimer&apos;s) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Glucokinase Activator (Diabetes)</masterLabel>
            <translation><!-- Glucokinase Activator (Diabetes) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>HCV Inhibitor Target 1 (Hepatitis C)</masterLabel>
            <translation><!-- HCV Inhibitor Target 1 (Hepatitis C) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>HCV Inhibitor Target 2 (Hepatitis C)</masterLabel>
            <translation><!-- HCV Inhibitor Target 2 (Hepatitis C) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>HCV Inhibitor Target 3 (Hepatitis C)</masterLabel>
            <translation><!-- HCV Inhibitor Target 3 (Hepatitis C) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>HCV Interferons</masterLabel>
            <translation><!-- HCV Interferons --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>HCV NS3/4A Protease Inhibitor</masterLabel>
            <translation><!-- HCV NS3/4A Protease Inhibitor --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>HCV NS5A</masterLabel>
            <translation><!-- HCV NS5A --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>HCV NS5B Polymerase Inhibitor (Nuc or Non-Nuc)</masterLabel>
            <translation><!-- HCV NS5B Polymerase Inhibitor (Nuc or Non-Nuc) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>HCV other cmpds</masterLabel>
            <translation><!-- HCV other cmpds --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>HIV Attachment Inhibitor (HIV/AIDS)</masterLabel>
            <translation><!-- HIV Attachment Inhibitor (HIV/AIDS) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>HIV Integrase Inhibitor (HIV/AIDS)</masterLabel>
            <translation><!-- HIV Integrase Inhibitor (HIV/AIDS) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>JAK2 inhibitor</masterLabel>
            <translation><!-- JAK2 inhibitor --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>LXR Agonist (Atherosclerosis)</masterLabel>
            <translation><!-- LXR Agonist (Atherosclerosis) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Microtubule Stabilizer (Alzheimer&apos;s)</masterLabel>
            <translation><!-- Microtubule Stabilizer (Alzheimer&apos;s) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Notch inhibitor</masterLabel>
            <translation><!-- Notch inhibitor --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>OPC-14597/Depot (Schizophrenia)</masterLabel>
            <translation><!-- OPC-14597/Depot (Schizophrenia) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>OPC-34712 (Schizophrenia, ADHD, adj in MDD)</masterLabel>
            <translation><!-- OPC-34712 (Schizophrenia, ADHD, adj in MDD) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Other (specify below)</masterLabel>
            <translation><!-- Other (specify below) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>PCSK9 Inhibitor (Cardiovascular)</masterLabel>
            <translation><!-- PCSK9 Inhibitor (Cardiovascular) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>SGLT2 inhibitor (Diabetes)</masterLabel>
            <translation><!-- SGLT2 inhibitor (Diabetes) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>SMO Inhibitor (Cancer)</masterLabel>
            <translation><!-- SMO Inhibitor (Cancer) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>TRUI (depression)</masterLabel>
            <translation><!-- TRUI (depression) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>p38 Kinase Inhibitors (Rheumatoid Arthritis)</masterLabel>
            <translation><!-- p38 Kinase Inhibitors (Rheumatoid Arthritis) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>rIL-21</masterLabel>
            <translation><!-- rIL-21 --></translation>
        </picklistValues>
    </fields>
    <fields>
        <label><!-- Full Development Product-Registrational --></label>
        <name>Full_Development_Product_BMS__c</name>
        <picklistValues>
            <masterLabel>Anti-PD-1 mAb</masterLabel>
            <translation><!-- Anti-PD-1 mAb --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Apixaban (Thrombosis)</masterLabel>
            <translation><!-- Apixaban (Thrombosis) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Brivanib (Cancer)</masterLabel>
            <translation><!-- Brivanib (Cancer) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Dapagliflozin (Diabetes)</masterLabel>
            <translation><!-- Dapagliflozin (Diabetes) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Elotuzumab</masterLabel>
            <translation><!-- Elotuzumab --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>IGF-1R/IR inhibitor</masterLabel>
            <translation><!-- IGF-1R/IR inhibitor --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Kombiglyze XR</masterLabel>
            <translation><!-- Kombiglyze XR --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Necitumumab</masterLabel>
            <translation><!-- Necitumumab --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Nivolumab</masterLabel>
            <translation><!-- Nivolumab --></translation>
        </picklistValues>
    </fields>
    <fields>
        <label><!-- Key Insight Topics --></label>
        <name>Key_Insight_Topics_BMS__c</name>
        <picklistValues>
            <masterLabel>ABILIFY - Bipolar Maintenance Trials:</masterLabel>
            <translation><!-- ABILIFY - Bipolar Maintenance Trials: --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>ABILIFY - OTHER</masterLabel>
            <translation><!-- ABILIFY - OTHER --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>ANTI PLATELET - Guidelines</masterLabel>
            <translation><!-- ANTI PLATELET - Guidelines --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>ANTI PLATELET - Prasugrel</masterLabel>
            <translation><!-- ANTI PLATELET - Prasugrel --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>ANTI PLATELET - Proton Pump Inhibitors (PPI) and Plavix</masterLabel>
            <translation><!-- ANTI PLATELET - Proton Pump Inhibitors (PPI) and Plavix --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>APIXABAN - Access of NOACs</masterLabel>
            <translation><!-- APIXABAN - Access of NOACs --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>APIXABAN - Bleeding Management</masterLabel>
            <translation><!-- APIXABAN - Bleeding Management --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>APIXABAN - Competitor Data Generation</masterLabel>
            <translation><!-- APIXABAN - Competitor Data Generation --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>APIXABAN - Differentiation between Eliquis and other Anticoagulants</masterLabel>
            <translation><!-- APIXABAN - Differentiation between Eliquis and other Anticoagulants --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>APIXABAN - Eliquis Data Generation</masterLabel>
            <translation><!-- APIXABAN - Eliquis Data Generation --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>APIXABAN - Other Key Topics (e.g. Guidelines, Publications)</masterLabel>
            <translation><!-- APIXABAN - Other Key Topics (e.g. Guidelines, Publications) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>APIXABAN - Speaker Insights</masterLabel>
            <translation><!-- APIXABAN - Speaker Insights --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>AVAPRO/AVALIDE - ARB/CCB fixed dose combination therapy</masterLabel>
            <translation><!-- AVAPRO/AVALIDE - ARB/CCB fixed dose combination therapy --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>AVAPRO/AVALIDE - Aliskiren</masterLabel>
            <translation><!-- AVAPRO/AVALIDE - Aliskiren --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>AVAPRO/AVALIDE - Antihypertensives</masterLabel>
            <translation><!-- AVAPRO/AVALIDE - Antihypertensives --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>AVAPRO/AVALIDE - Atrial Fibrillation</masterLabel>
            <translation><!-- AVAPRO/AVALIDE - Atrial Fibrillation --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>AVAPRO/AVALIDE - Congress Information</masterLabel>
            <translation><!-- AVAPRO/AVALIDE - Congress Information --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>AVAPRO/AVALIDE - Guidelines</masterLabel>
            <translation><!-- AVAPRO/AVALIDE - Guidelines --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>AVAPRO/AVALIDE - Heart Failure</masterLabel>
            <translation><!-- AVAPRO/AVALIDE - Heart Failure --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>AVAPRO/AVALIDE - Initial combination therapy</masterLabel>
            <translation><!-- AVAPRO/AVALIDE - Initial combination therapy --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>AVAPRO/AVALIDE - Metabolic Syndrome</masterLabel>
            <translation><!-- AVAPRO/AVALIDE - Metabolic Syndrome --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>AVAPRO/AVALIDE - Ongoing antihypertensive studies, including but not limited to</masterLabel>
            <translation><!-- AVAPRO/AVALIDE - Ongoing antihypertensive studies, including but not limited to --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Abilify - ASENAPINE</masterLabel>
            <translation><!-- Abilify - ASENAPINE --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Abilify - BMS Concerns</masterLabel>
            <translation><!-- Abilify - BMS Concerns --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Abilify - Bipolar Maintenance Trials</masterLabel>
            <translation><!-- Abilify - Bipolar Maintenance Trials --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Abilify - CARIPRAZINE</masterLabel>
            <translation><!-- Abilify - CARIPRAZINE --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Abilify - DSM 5</masterLabel>
            <translation><!-- Abilify - DSM 5 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Abilify - LURASIDONE</masterLabel>
            <translation><!-- Abilify - LURASIDONE --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Abilify - MDD:  General</masterLabel>
            <translation><!-- Abilify - MDD:  General --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Abilify - MDD: General</masterLabel>
            <translation><!-- Abilify - MDD: General --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Abilify - Medical Questions</masterLabel>
            <translation><!-- Abilify - Medical Questions --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Abilify - Other (Please Specify)</masterLabel>
            <translation><!-- Abilify - Other (Please Specify) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Abilify - PEDIATRICS: General</masterLabel>
            <translation><!-- Abilify - PEDIATRICS: General --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Abilify - Payer Strategy</masterLabel>
            <translation><!-- Abilify - Payer Strategy --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Abilify - QUETIAPINE XR</masterLabel>
            <translation><!-- Abilify - QUETIAPINE XR --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Abilify - Regulatory and Patent Issues</masterLabel>
            <translation><!-- Abilify - Regulatory and Patent Issues --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Abilify - Revised APA Guidelines for MDD</masterLabel>
            <translation><!-- Abilify - Revised APA Guidelines for MDD --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Apixaban - Anticoagulation therapy in AF</masterLabel>
            <translation><!-- Apixaban - Anticoagulation therapy in AF --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Apixaban - Apixaban</masterLabel>
            <translation><!-- Apixaban - Apixaban --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Apixaban - Competitors (Factor Xa Inhibitors and DTIs) in AF</masterLabel>
            <translation><!-- Apixaban - Competitors (Factor Xa Inhibitors and DTIs) in AF --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Apixaban - Other (Please Specify)</masterLabel>
            <translation><!-- Apixaban - Other (Please Specify) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Avagacestat (Gamma Secretase Inhibitor) - Biomarkers &amp; Diagnostics</masterLabel>
            <translation><!-- Avagacestat (Gamma Secretase Inhibitor) - Biomarkers &amp; Diagnostics --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Avagacestat (Gamma Secretase Inhibitor) - Education and Awareness</masterLabel>
            <translation><!-- Avagacestat (Gamma Secretase Inhibitor) - Education and Awareness --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Avagacestat (Gamma Secretase Inhibitor) - Neuroimaging</masterLabel>
            <translation><!-- Avagacestat (Gamma Secretase Inhibitor) - Neuroimaging --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Avagacestat (Gamma Secretase Inhibitor) - Other (Please Specify)</masterLabel>
            <translation><!-- Avagacestat (Gamma Secretase Inhibitor) - Other (Please Specify) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Avagacestat (Gamma Secretase Inhibitor) - Patient Flow</masterLabel>
            <translation><!-- Avagacestat (Gamma Secretase Inhibitor) - Patient Flow --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Avagacestat (Gamma Secretase Inhibitor) - Stakeholders Insights</masterLabel>
            <translation><!-- Avagacestat (Gamma Secretase Inhibitor) - Stakeholders Insights --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>BARACLUDE - ANTIVIRAL THERAPY</masterLabel>
            <translation><!-- BARACLUDE - ANTIVIRAL THERAPY --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>BARACLUDE - COMPETITOR ACTIVITY</masterLabel>
            <translation><!-- BARACLUDE - COMPETITOR ACTIVITY --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>BARACLUDE - DISEASE STATE/GUIDELINES</masterLabel>
            <translation><!-- BARACLUDE - DISEASE STATE/GUIDELINES --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>BARACLUDE - PAYOR STRATEGY</masterLabel>
            <translation><!-- BARACLUDE - PAYOR STRATEGY --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>BELATACEPT - Belatacept specific</masterLabel>
            <translation><!-- BELATACEPT - Belatacept specific --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>BELATACEPT - Payer</masterLabel>
            <translation><!-- BELATACEPT - Payer --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>BELATACEPT - REMS/Registry</masterLabel>
            <translation><!-- BELATACEPT - REMS/Registry --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>BELATACEPT - Research interests</masterLabel>
            <translation><!-- BELATACEPT - Research interests --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>BELATACEPT - Suggested data gap analyis</masterLabel>
            <translation><!-- BELATACEPT - Suggested data gap analyis --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>BRIVANIB -  ANTI-ANGIOGENIC THERAPY and TKI:</masterLabel>
            <translation><!-- BRIVANIB -  ANTI-ANGIOGENIC THERAPY and TKI: --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>BRIVANIB -  BIOMARKERS:</masterLabel>
            <translation><!-- BRIVANIB -  BIOMARKERS: --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>BRIVANIB - ANTI-ANGIOGENIC THERAPY and TKI:</masterLabel>
            <translation><!-- BRIVANIB - ANTI-ANGIOGENIC THERAPY and TKI: --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>BRIVANIB - BIOMARKERS:</masterLabel>
            <translation><!-- BRIVANIB - BIOMARKERS: --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>BRIVANIB - COMPETITIVE LANDSCAPE</masterLabel>
            <translation><!-- BRIVANIB - COMPETITIVE LANDSCAPE --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>BRIVANIB - NEW PARADIGMS in LIVER DISEASES:</masterLabel>
            <translation><!-- BRIVANIB - NEW PARADIGMS in LIVER DISEASES: --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>BRIVANIB - TUMOR ASSESSEMENT CRITERIA:</masterLabel>
            <translation><!-- BRIVANIB - TUMOR ASSESSEMENT CRITERIA: --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>ERBITUX - Biomarkers:</masterLabel>
            <translation><!-- ERBITUX - Biomarkers: --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>ERBITUX - Competitive Intelligence:</masterLabel>
            <translation><!-- ERBITUX - Competitive Intelligence: --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>ERBITUX - Impact of Cost and Treatment Pathways (specify Tumor type if known)</masterLabel>
            <translation><!-- ERBITUX - Impact of Cost and Treatment Pathways (specify Tumor type if known) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>ERBITUX - MOA (ALL):</masterLabel>
            <translation><!-- ERBITUX - MOA (ALL): --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>ERBITUX - NSCLC Landscape/Treatment Paradigms:</masterLabel>
            <translation><!-- ERBITUX - NSCLC Landscape/Treatment Paradigms: --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>ERBITUX - SCCHN Landscape/Treatment Paradigms:</masterLabel>
            <translation><!-- ERBITUX - SCCHN Landscape/Treatment Paradigms: --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>ERBITUX - Safety concerns and management strategies:</masterLabel>
            <translation><!-- ERBITUX - Safety concerns and management strategies: --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>ERBITUX - mCRC Landscape/Treatment Paradigms:</masterLabel>
            <translation><!-- ERBITUX - mCRC Landscape/Treatment Paradigms: --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>GAMMA - Biomarkers &amp; Diagnostics</masterLabel>
            <translation><!-- GAMMA - Biomarkers &amp; Diagnostics --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>GAMMA - Education and Awareness:</masterLabel>
            <translation><!-- GAMMA - Education and Awareness: --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>GAMMA - Neuroimaging</masterLabel>
            <translation><!-- GAMMA - Neuroimaging --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>GAMMA - Patient Flow:</masterLabel>
            <translation><!-- GAMMA - Patient Flow: --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>GAMMA - Stakeholders Insights</masterLabel>
            <translation><!-- GAMMA - Stakeholders Insights --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>HIV - Darunavir</masterLabel>
            <translation><!-- HIV - Darunavir --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>HIV - Dolutegravir</masterLabel>
            <translation><!-- HIV - Dolutegravir --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>HIV - Payer Strategy</masterLabel>
            <translation><!-- HIV - Payer Strategy --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>HIV - Positive Charge</masterLabel>
            <translation><!-- HIV - Positive Charge --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>HIV - Quad</masterLabel>
            <translation><!-- HIV - Quad --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>HIV - Raltegavir</masterLabel>
            <translation><!-- HIV - Raltegavir --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>HIV - Rilpivirine/Complera</masterLabel>
            <translation><!-- HIV - Rilpivirine/Complera --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>HIV - Trial information, competitor information, etc</masterLabel>
            <translation><!-- HIV - Trial information, competitor information, etc --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>HIV General / Reyataz / Sustiva / Atripla - Darunavir</masterLabel>
            <translation><!-- HIV General / Reyataz / Sustiva / Atripla - Darunavir --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>HIV General / Reyataz / Sustiva / Atripla - Dolutegravir</masterLabel>
            <translation><!-- HIV General / Reyataz / Sustiva / Atripla - Dolutegravir --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>HIV General / Reyataz / Sustiva / Atripla - Other (Please Specify)</masterLabel>
            <translation><!-- HIV General / Reyataz / Sustiva / Atripla - Other (Please Specify) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>HIV General / Reyataz / Sustiva / Atripla - Payer Strategy</masterLabel>
            <translation><!-- HIV General / Reyataz / Sustiva / Atripla - Payer Strategy --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>HIV General / Reyataz / Sustiva / Atripla - Positive Charge</masterLabel>
            <translation><!-- HIV General / Reyataz / Sustiva / Atripla - Positive Charge --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>HIV General / Reyataz / Sustiva / Atripla - Quad</masterLabel>
            <translation><!-- HIV General / Reyataz / Sustiva / Atripla - Quad --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>HIV General / Reyataz / Sustiva / Atripla - Raltegavir</masterLabel>
            <translation><!-- HIV General / Reyataz / Sustiva / Atripla - Raltegavir --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>HIV General / Reyataz / Sustiva / Atripla - Rilpivirine/Complera</masterLabel>
            <translation><!-- HIV General / Reyataz / Sustiva / Atripla - Rilpivirine/Complera --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>HIV General / Reyataz / Sustiva / Atripla - Trial information, competitor information, etc</masterLabel>
            <translation><!-- HIV General / Reyataz / Sustiva / Atripla - Trial information, competitor information, etc --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Hepatitis General / Baraclude - COMPETITOR ACTIVITY</masterLabel>
            <translation><!-- Hepatitis General / Baraclude - COMPETITOR ACTIVITY --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Hepatitis General / Baraclude - DISEASE STATE/SPECIAL POPULATIONS</masterLabel>
            <translation><!-- Hepatitis General / Baraclude - DISEASE STATE/SPECIAL POPULATIONS --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Hepatitis General / Baraclude - Other (Please Specify)</masterLabel>
            <translation><!-- Hepatitis General / Baraclude - Other (Please Specify) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Hepatitis General / Baraclude - PAYER STRATEGY</masterLabel>
            <translation><!-- Hepatitis General / Baraclude - PAYER STRATEGY --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Hepatitis General / Baraclude - TENOFOVIR</masterLabel>
            <translation><!-- Hepatitis General / Baraclude - TENOFOVIR --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>IMS General  / Orencia - Biomarkers</masterLabel>
            <translation><!-- IMS General  / Orencia - Biomarkers --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>IMS General  / Orencia - Clinical trials (information on)</masterLabel>
            <translation><!-- IMS General  / Orencia - Clinical trials (information on) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>IMS General  / Orencia - Current Products</masterLabel>
            <translation><!-- IMS General  / Orencia - Current Products --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>IMS General  / Orencia - Education</masterLabel>
            <translation><!-- IMS General  / Orencia - Education --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>IMS General  / Orencia - Efficacy</masterLabel>
            <translation><!-- IMS General  / Orencia - Efficacy --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>IMS General  / Orencia - Future Products/Indications</masterLabel>
            <translation><!-- IMS General  / Orencia - Future Products/Indications --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>IMS General  / Orencia - IL-6</masterLabel>
            <translation><!-- IMS General  / Orencia - IL-6 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>IMS General  / Orencia - Managed Markets/Patient Assistance</masterLabel>
            <translation><!-- IMS General  / Orencia - Managed Markets/Patient Assistance --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>IMS General  / Orencia - Novel RA Trial Design (other H2H/VERA/Remission induction/retention studies, etc.)</masterLabel>
            <translation><!-- IMS General  / Orencia - Novel RA Trial Design (other H2H/VERA/Remission induction/retention studies, etc.) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>IMS General  / Orencia - Other (Please Specify)</masterLabel>
            <translation><!-- IMS General  / Orencia - Other (Please Specify) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>IMS General  / Orencia - Other Small Molecule compounds for RA (e.g. JAK, Syk, CCR1, BTK, etc.)</masterLabel>
            <translation><!-- IMS General  / Orencia - Other Small Molecule compounds for RA (e.g. JAK, Syk, CCR1, BTK, etc.) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>IMS General  / Orencia - Safety</masterLabel>
            <translation><!-- IMS General  / Orencia - Safety --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>IMS General  / Orencia - fostamatinib (Syk inhibitor)</masterLabel>
            <translation><!-- IMS General  / Orencia - fostamatinib (Syk inhibitor) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>IMS General  / Orencia - tofacitinib/tasocitinib (JAK-3) Pfizer</masterLabel>
            <translation><!-- IMS General  / Orencia - tofacitinib/tasocitinib (JAK-3) Pfizer --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>IMS General / Orencia - Biomarkers</masterLabel>
            <translation><!-- IMS General / Orencia - Biomarkers --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>IMS General / Orencia - Clinical trials (information on)</masterLabel>
            <translation><!-- IMS General / Orencia - Clinical trials (information on) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>IMS General / Orencia - Current Products</masterLabel>
            <translation><!-- IMS General / Orencia - Current Products --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>IMS General / Orencia - Education</masterLabel>
            <translation><!-- IMS General / Orencia - Education --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>IMS General / Orencia - Efficacy</masterLabel>
            <translation><!-- IMS General / Orencia - Efficacy --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>IMS General / Orencia - Future Products/Indications</masterLabel>
            <translation><!-- IMS General / Orencia - Future Products/Indications --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>IMS General / Orencia - IL-6</masterLabel>
            <translation><!-- IMS General / Orencia - IL-6 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>IMS General / Orencia - Managed Markets/Patient Assistance</masterLabel>
            <translation><!-- IMS General / Orencia - Managed Markets/Patient Assistance --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>IMS General / Orencia - Novel RA Trial Design (other H2H/VERA/Remission induction/retention studies, etc.)</masterLabel>
            <translation><!-- IMS General / Orencia - Novel RA Trial Design (other H2H/VERA/Remission induction/retention studies, etc.) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>IMS General / Orencia - Other (Please Specify)</masterLabel>
            <translation><!-- IMS General / Orencia - Other (Please Specify) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>IMS General / Orencia - Other Small Molecule compounds for RA (e.g. JAK, Syk, CCR1, BTK, etc.)</masterLabel>
            <translation><!-- IMS General / Orencia - Other Small Molecule compounds for RA (e.g. JAK, Syk, CCR1, BTK, etc.) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>IMS General / Orencia - Safety</masterLabel>
            <translation><!-- IMS General / Orencia - Safety --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>IMS General / Orencia - fostamatinib (Syk inhibitor)</masterLabel>
            <translation><!-- IMS General / Orencia - fostamatinib (Syk inhibitor) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>IMS General / Orencia - tofacitinib/tasocitinib (JAK-3) Pfizer</masterLabel>
            <translation><!-- IMS General / Orencia - tofacitinib/tasocitinib (JAK-3) Pfizer --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>NEW ONGLYZA - CV outcomes and LCM studies w. DPP-4is and GLP-1s</masterLabel>
            <translation><!-- NEW ONGLYZA - CV outcomes and LCM studies w. DPP-4is and GLP-1s --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>NEW ONGLYZA - FDC</masterLabel>
            <translation><!-- NEW ONGLYZA - FDC --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>NEW ONGLYZA - Future DPP4-I launches</masterLabel>
            <translation><!-- NEW ONGLYZA - Future DPP4-I launches --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>NEW ONGLYZA - GLP-1 Agonists</masterLabel>
            <translation><!-- NEW ONGLYZA - GLP-1 Agonists --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>NEW ONGLYZA - Guidelines/algorithms/position statements</masterLabel>
            <translation><!-- NEW ONGLYZA - Guidelines/algorithms/position statements --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>NEW ONGLYZA - Januvia Medical Strategy</masterLabel>
            <translation><!-- NEW ONGLYZA - Januvia Medical Strategy --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>NS EXPLORATORY - Depression landscape</masterLabel>
            <translation><!-- NS EXPLORATORY - Depression landscape --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>NS EXPLORATORY - Specific Competitors</masterLabel>
            <translation><!-- NS EXPLORATORY - Specific Competitors --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>NS General - Depression landscape</masterLabel>
            <translation><!-- NS General - Depression landscape --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>NS General - Other (Please Specify)</masterLabel>
            <translation><!-- NS General - Other (Please Specify) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>NS General - PAYER LANDSCAPE</masterLabel>
            <translation><!-- NS General - PAYER LANDSCAPE --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>NS General - Specific Competitors</masterLabel>
            <translation><!-- NS General - Specific Competitors --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>NS MARKETING - PRIMARY</masterLabel>
            <translation><!-- NS MARKETING - PRIMARY --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>NS MARKETING - SECONDARY</masterLabel>
            <translation><!-- NS MARKETING - SECONDARY --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>NULOJIX - AR</masterLabel>
            <translation><!-- NULOJIX - AR --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>NULOJIX - Access</masterLabel>
            <translation><!-- NULOJIX - Access --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>NULOJIX - Alternate Induction</masterLabel>
            <translation><!-- NULOJIX - Alternate Induction --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>NULOJIX - Competitor</masterLabel>
            <translation><!-- NULOJIX - Competitor --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>NULOJIX - Disease State</masterLabel>
            <translation><!-- NULOJIX - Disease State --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>NULOJIX - Health Outcomes</masterLabel>
            <translation><!-- NULOJIX - Health Outcomes --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>NULOJIX - Investigational Ideas</masterLabel>
            <translation><!-- NULOJIX - Investigational Ideas --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>NULOJIX - Liver</masterLabel>
            <translation><!-- NULOJIX - Liver --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>NULOJIX - Misc</masterLabel>
            <translation><!-- NULOJIX - Misc --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>NULOJIX - Other Organs (non-renal/liver)</masterLabel>
            <translation><!-- NULOJIX - Other Organs (non-renal/liver) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>NULOJIX - PK/PD</masterLabel>
            <translation><!-- NULOJIX - PK/PD --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>NULOJIX - Patient and Graft Survival</masterLabel>
            <translation><!-- NULOJIX - Patient and Graft Survival --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>NULOJIX - Renal Function and Structure</masterLabel>
            <translation><!-- NULOJIX - Renal Function and Structure --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>NULOJIX - Safety and CV/MET</masterLabel>
            <translation><!-- NULOJIX - Safety and CV/MET --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>NULOJIX - Special Populations</masterLabel>
            <translation><!-- NULOJIX - Special Populations --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>NULOJIX - Steriod avoiding regimens</masterLabel>
            <translation><!-- NULOJIX - Steriod avoiding regimens --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>NULOJIX - Switch</masterLabel>
            <translation><!-- NULOJIX - Switch --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>NULOJIX - Use of Belatacept</masterLabel>
            <translation><!-- NULOJIX - Use of Belatacept --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>NULOJIX  - AR</masterLabel>
            <translation><!-- NULOJIX  - AR --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>NULOJIX  - Access</masterLabel>
            <translation><!-- NULOJIX  - Access --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>NULOJIX  - Alternate Induction</masterLabel>
            <translation><!-- NULOJIX  - Alternate Induction --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>NULOJIX  - Competitor</masterLabel>
            <translation><!-- NULOJIX  - Competitor --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>NULOJIX  - Disease State</masterLabel>
            <translation><!-- NULOJIX  - Disease State --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>NULOJIX  - Health Outcomes</masterLabel>
            <translation><!-- NULOJIX  - Health Outcomes --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>NULOJIX  - Investigational Ideas</masterLabel>
            <translation><!-- NULOJIX  - Investigational Ideas --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>NULOJIX  - Liver</masterLabel>
            <translation><!-- NULOJIX  - Liver --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>NULOJIX  - Misc</masterLabel>
            <translation><!-- NULOJIX  - Misc --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>NULOJIX  - Other Organs (non-renal/liver)</masterLabel>
            <translation><!-- NULOJIX  - Other Organs (non-renal/liver) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>NULOJIX  - PK/PD</masterLabel>
            <translation><!-- NULOJIX  - PK/PD --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>NULOJIX  - Patient and Graft Survival</masterLabel>
            <translation><!-- NULOJIX  - Patient and Graft Survival --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>NULOJIX  - Renal Function and Structure</masterLabel>
            <translation><!-- NULOJIX  - Renal Function and Structure --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>NULOJIX  - Safety and CV/MET</masterLabel>
            <translation><!-- NULOJIX  - Safety and CV/MET --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>NULOJIX  - Special Populations</masterLabel>
            <translation><!-- NULOJIX  - Special Populations --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>NULOJIX  - Switch</masterLabel>
            <translation><!-- NULOJIX  - Switch --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>NULOJIX  - Use of Belatacept</masterLabel>
            <translation><!-- NULOJIX  - Use of Belatacept --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Nivolumab -Additional Tumor Types</masterLabel>
            <translation><!-- Nivolumab -Additional Tumor Types --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Nivolumab -Biomarkers</masterLabel>
            <translation><!-- Nivolumab -Biomarkers --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Nivolumab -Clinical Study Involvement/Compassionate Use</masterLabel>
            <translation><!-- Nivolumab -Clinical Study Involvement/Compassionate Use --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Nivolumab -Competitive Intelligence</masterLabel>
            <translation><!-- Nivolumab -Competitive Intelligence --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Nivolumab -MOA</masterLabel>
            <translation><!-- Nivolumab -MOA --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Nivolumab -NSCLC Treatment Landscape/Paradigms</masterLabel>
            <translation><!-- Nivolumab -NSCLC Treatment Landscape/Paradigms --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Nivolumab -Safety Concerns/Management Strategies</masterLabel>
            <translation><!-- Nivolumab -Safety Concerns/Management Strategies --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>ONCOLOGY - AR antagonist (prostate cancer)</masterLabel>
            <translation><!-- ONCOLOGY - AR antagonist (prostate cancer) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>ONCOLOGY - Anti CD-137 (melanoma, RCC)</masterLabel>
            <translation><!-- ONCOLOGY - Anti CD-137 (melanoma, RCC) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>ONCOLOGY - Brivanib alaninate (VEGFR/FGFR inhibitor) (solid tumors: HCC, CRC)</masterLabel>
            <translation><!-- ONCOLOGY - Brivanib alaninate (VEGFR/FGFR inhibitor) (solid tumors: HCC, CRC) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>ONCOLOGY - Eothilone folate (solid tumors)</masterLabel>
            <translation><!-- ONCOLOGY - Eothilone folate (solid tumors) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>ONCOLOGY - ErbB/VEGF receptor inhibitor (solid tumors)</masterLabel>
            <translation><!-- ONCOLOGY - ErbB/VEGF receptor inhibitor (solid tumors) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>ONCOLOGY - For MORAb-003 (Phase II, Morphotek):</masterLabel>
            <translation><!-- ONCOLOGY - For MORAb-003 (Phase II, Morphotek): --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>ONCOLOGY - IGF-1R antagonist (solid tumors)</masterLabel>
            <translation><!-- ONCOLOGY - IGF-1R antagonist (solid tumors) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>ONCOLOGY - Ipilimumab (CTLA-4 receptor antagonist) (melanoma)</masterLabel>
            <translation><!-- ONCOLOGY - Ipilimumab (CTLA-4 receptor antagonist) (melanoma) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>ONCOLOGY - Ixabepilone (tubulin polymerization) (solid tumors)</masterLabel>
            <translation><!-- ONCOLOGY - Ixabepilone (tubulin polymerization) (solid tumors) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>ONCOLOGY - Met kinase inhibitor (solid tumors)</masterLabel>
            <translation><!-- ONCOLOGY - Met kinase inhibitor (solid tumors) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>ORENCIA - Actemra</masterLabel>
            <translation><!-- ORENCIA - Actemra --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>ORENCIA - Actemra/Humira</masterLabel>
            <translation><!-- ORENCIA - Actemra/Humira --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>ORENCIA - All competitor products</masterLabel>
            <translation><!-- ORENCIA - All competitor products --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>ORENCIA - Cimzia/Humira</masterLabel>
            <translation><!-- ORENCIA - Cimzia/Humira --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>ORENCIA - Competitor Insights</masterLabel>
            <translation><!-- ORENCIA - Competitor Insights --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>ORENCIA - JAK Inhibitor(s)</masterLabel>
            <translation><!-- ORENCIA - JAK Inhibitor(s) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>ORENCIA - Orencia</masterLabel>
            <translation><!-- ORENCIA - Orencia --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>ORENCIA - Payer</masterLabel>
            <translation><!-- ORENCIA - Payer --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Oncology General - AR antagonist (prostate cancer)</masterLabel>
            <translation><!-- Oncology General - AR antagonist (prostate cancer) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Oncology General - Brivanib alaninate (VEGFR/FGFR inhibitor) (solid tumors: HCC, CRC)</masterLabel>
            <translation><!-- Oncology General - Brivanib alaninate (VEGFR/FGFR inhibitor) (solid tumors: HCC, CRC) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Oncology General - ErbB/VEGF receptor inhibitor (solid tumors)</masterLabel>
            <translation><!-- Oncology General - ErbB/VEGF receptor inhibitor (solid tumors) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Oncology General - For MORAb-003 (Phase II, Morphotek):</masterLabel>
            <translation><!-- Oncology General - For MORAb-003 (Phase II, Morphotek): --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Oncology General - IGF-1R antagonist (solid tumors)</masterLabel>
            <translation><!-- Oncology General - IGF-1R antagonist (solid tumors) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Oncology General - Ipilimumab (CTLA-4 receptor antagonist) (melanoma)</masterLabel>
            <translation><!-- Oncology General - Ipilimumab (CTLA-4 receptor antagonist) (melanoma) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Oncology General - Ixabepilone (tubulin polymerization) (solid tumors)</masterLabel>
            <translation><!-- Oncology General - Ixabepilone (tubulin polymerization) (solid tumors) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Oncology General - Met kinase inhibitor (solid tumors)</masterLabel>
            <translation><!-- Oncology General - Met kinase inhibitor (solid tumors) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Oncology General - anti CD-137 (melanoma, RCC)</masterLabel>
            <translation><!-- Oncology General - anti CD-137 (melanoma, RCC) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Oncology General - epothilone folate (solid tumors)</masterLabel>
            <translation><!-- Oncology General - epothilone folate (solid tumors) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Onglyza - CV outcomes and LCM studies w. DPP-4is and GLP-1s</masterLabel>
            <translation><!-- Onglyza - CV outcomes and LCM studies w. DPP-4is and GLP-1s --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Onglyza - FDC</masterLabel>
            <translation><!-- Onglyza - FDC --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Onglyza - Future DPP4-I launches</masterLabel>
            <translation><!-- Onglyza - Future DPP4-I launches --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Onglyza - GLP-1 Agonists</masterLabel>
            <translation><!-- Onglyza - GLP-1 Agonists --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Onglyza - Guidelines/algorithms/position statements</masterLabel>
            <translation><!-- Onglyza - Guidelines/algorithms/position statements --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Onglyza - Januvia Medical Strategy</masterLabel>
            <translation><!-- Onglyza - Januvia Medical Strategy --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Onglyza - Other (Please Specify)</masterLabel>
            <translation><!-- Onglyza - Other (Please Specify) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>PLAVIX - Prasugrel</masterLabel>
            <translation><!-- PLAVIX - Prasugrel --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>PLAVIX - Ticagrelor</masterLabel>
            <translation><!-- PLAVIX - Ticagrelor --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>PLAVIX - VOR</masterLabel>
            <translation><!-- PLAVIX - VOR --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>SPRYCEL - Biomarkers:</masterLabel>
            <translation><!-- SPRYCEL - Biomarkers: --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>SPRYCEL - CML Landscape/Treatment Paradigms:</masterLabel>
            <translation><!-- SPRYCEL - CML Landscape/Treatment Paradigms: --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>SPRYCEL - Competitive Intelligence:</masterLabel>
            <translation><!-- SPRYCEL - Competitive Intelligence: --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>SPRYCEL - Impact of cost and Treatment Pathways:</masterLabel>
            <translation><!-- SPRYCEL - Impact of cost and Treatment Pathways: --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>SPRYCEL - Mutations:</masterLabel>
            <translation><!-- SPRYCEL - Mutations: --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>SPRYCEL - Outcomes research:</masterLabel>
            <translation><!-- SPRYCEL - Outcomes research: --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>SPRYCEL - Research Interest</masterLabel>
            <translation><!-- SPRYCEL - Research Interest --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>SPRYCEL - Safety concerns and management strategies:</masterLabel>
            <translation><!-- SPRYCEL - Safety concerns and management strategies: --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>TRUI - Algorithm placement</masterLabel>
            <translation><!-- TRUI - Algorithm placement --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>TRUI - Biomarkers of depression</masterLabel>
            <translation><!-- TRUI - Biomarkers of depression --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>TRUI - Dopamine As A Unique Target</masterLabel>
            <translation><!-- TRUI - Dopamine As A Unique Target --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>TRUI - Patient type</masterLabel>
            <translation><!-- TRUI - Patient type --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>TRUI - Payor</masterLabel>
            <translation><!-- TRUI - Payor --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>TRUI - Trial design</masterLabel>
            <translation><!-- TRUI - Trial design --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Triple Reuptake Inhibitors - Algorithm placement</masterLabel>
            <translation><!-- Triple Reuptake Inhibitors - Algorithm placement --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Triple Reuptake Inhibitors - Biomarkers of depression</masterLabel>
            <translation><!-- Triple Reuptake Inhibitors - Biomarkers of depression --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Triple Reuptake Inhibitors - Dopamine As A Unique Target</masterLabel>
            <translation><!-- Triple Reuptake Inhibitors - Dopamine As A Unique Target --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Triple Reuptake Inhibitors - Other (Please Specify)</masterLabel>
            <translation><!-- Triple Reuptake Inhibitors - Other (Please Specify) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Triple Reuptake Inhibitors - Patient type</masterLabel>
            <translation><!-- Triple Reuptake Inhibitors - Patient type --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Triple Reuptake Inhibitors - Payor</masterLabel>
            <translation><!-- Triple Reuptake Inhibitors - Payor --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Triple Reuptake Inhibitors - Trial design</masterLabel>
            <translation><!-- Triple Reuptake Inhibitors - Trial design --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>YERVOY - Adj Mel-Yervoy Related Treatment and Management Practices</masterLabel>
            <translation><!-- YERVOY - Adj Mel-Yervoy Related Treatment and Management Practices --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>YERVOY - Adv Mel -Biomarkers</masterLabel>
            <translation><!-- YERVOY - Adv Mel -Biomarkers --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>YERVOY - Adv Mel -Melanoma Competitive Landscape/Treatment Paradigms</masterLabel>
            <translation><!-- YERVOY - Adv Mel -Melanoma Competitive Landscape/Treatment Paradigms --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>YERVOY - Adv Mel-Treatment Landscape</masterLabel>
            <translation><!-- YERVOY - Adv Mel-Treatment Landscape --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>YERVOY - Adv Mel-YERVOY Related Treatment and Management Practices</masterLabel>
            <translation><!-- YERVOY - Adv Mel-YERVOY Related Treatment and Management Practices --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>YERVOY - NSCLC and SCLC-Landscape/Treatment Paradigms</masterLabel>
            <translation><!-- YERVOY - NSCLC and SCLC-Landscape/Treatment Paradigms --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>YERVOY - NSCLC and SCLC-Safety concerns and management strategies</masterLabel>
            <translation><!-- YERVOY - NSCLC and SCLC-Safety concerns and management strategies --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>YERVOY - NSCLC and SCLC-YERVOY Related Treatment and Management Practices</masterLabel>
            <translation><!-- YERVOY - NSCLC and SCLC-YERVOY Related Treatment and Management Practices --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>YERVOY - mCRPC-Landscape/Treatment Paradigms</masterLabel>
            <translation><!-- YERVOY - mCRPC-Landscape/Treatment Paradigms --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>YERVOY - mCRPC-Safety concerns and management strategies</masterLabel>
            <translation><!-- YERVOY - mCRPC-Safety concerns and management strategies --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>YERVOY - mCRPC-YERVOY Related Treatment and Management Practices</masterLabel>
            <translation><!-- YERVOY - mCRPC-YERVOY Related Treatment and Management Practices --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>YERVOY™ (ipilimumab) - Adjuvant Melanoma Landscape/Treatment Paradigms</masterLabel>
            <translation><!-- YERVOY™ (ipilimumab) - Adjuvant Melanoma Landscape/Treatment Paradigms --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>YERVOY™ (ipilimumab) - Advanced Melanoma Landscape/Treatment Paradigms</masterLabel>
            <translation><!-- YERVOY™ (ipilimumab) - Advanced Melanoma Landscape/Treatment Paradigms --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>YERVOY™ (ipilimumab) - Biomarkers</masterLabel>
            <translation><!-- YERVOY™ (ipilimumab) - Biomarkers --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>YERVOY™ (ipilimumab) - Competitive Intelligence</masterLabel>
            <translation><!-- YERVOY™ (ipilimumab) - Competitive Intelligence --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>YERVOY™ (ipilimumab) - Gastric Landscape/Treatment Paradigms</masterLabel>
            <translation><!-- YERVOY™ (ipilimumab) - Gastric Landscape/Treatment Paradigms --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>YERVOY™ (ipilimumab) - Impact of cost and Treatment Pathways</masterLabel>
            <translation><!-- YERVOY™ (ipilimumab) - Impact of cost and Treatment Pathways --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>YERVOY™ (ipilimumab) - MOA</masterLabel>
            <translation><!-- YERVOY™ (ipilimumab) - MOA --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>YERVOY™ (ipilimumab) - Other (Please Specify)</masterLabel>
            <translation><!-- YERVOY™ (ipilimumab) - Other (Please Specify) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>YERVOY™ (ipilimumab) - Ovarian Landscape/Treatment Paradigms</masterLabel>
            <translation><!-- YERVOY™ (ipilimumab) - Ovarian Landscape/Treatment Paradigms --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>YERVOY™ (ipilimumab) - REMS</masterLabel>
            <translation><!-- YERVOY™ (ipilimumab) - REMS --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>YERVOY™ (ipilimumab) - Safety concerns and management strategies</masterLabel>
            <translation><!-- YERVOY™ (ipilimumab) - Safety concerns and management strategies --></translation>
        </picklistValues>
    </fields>
    <fields>
        <label><!-- Life Cycle Management Product --></label>
        <name>Life_Cycle_Management_Product_BMS__c</name>
        <picklistValues>
            <masterLabel>ABILIFY</masterLabel>
            <translation><!-- ABILIFY --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>AVAPRO / AVALIDE</masterLabel>
            <translation><!-- AVAPRO / AVALIDE --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>BARACLUDE</masterLabel>
            <translation><!-- BARACLUDE --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>BYDUREON</masterLabel>
            <translation><!-- BYDUREON --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>BYETTA</masterLabel>
            <translation><!-- BYETTA --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>ELIQUIS</masterLabel>
            <translation><!-- ELIQUIS --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>ERBITUX</masterLabel>
            <translation><!-- ERBITUX --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>IXEMPRA</masterLabel>
            <translation><!-- IXEMPRA --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>KOMBIGLYZE XR</masterLabel>
            <translation><!-- KOMBIGLYZE XR --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>NULOJIX</masterLabel>
            <translation><!-- NULOJIX --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>ONGLYZA</masterLabel>
            <translation><!-- ONGLYZA --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>ORENCIA</masterLabel>
            <translation><!-- ORENCIA --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>PLAVIX</masterLabel>
            <translation><!-- PLAVIX --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>RECOTHROM</masterLabel>
            <translation><!-- RECOTHROM --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>REYATAZ / SUSTIVA / ATRIPLA</masterLabel>
            <translation><!-- REYATAZ / SUSTIVA / ATRIPLA --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>SPRYCEL</masterLabel>
            <translation><!-- SPRYCEL --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>YERVOY</masterLabel>
            <translation><!-- YERVOY --></translation>
        </picklistValues>
    </fields>
    <fields>
        <label>Type de connaissance médicale</label>
        <name>Medical_Insight_Source_Type_BMS__c</name>
        <picklistValues>
            <masterLabel>Allied Health Professional</masterLabel>
            <translation><!-- Allied Health Professional --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Cardiology</masterLabel>
            <translation><!-- Cardiology --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Emergency Medicine</masterLabel>
            <translation><!-- Emergency Medicine --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Family Practice/Internal Medicine</masterLabel>
            <translation><!-- Family Practice/Internal Medicine --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Formulary Management</masterLabel>
            <translation><!-- Formulary Management --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>HCP</masterLabel>
            <translation><!-- HCP --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Hematology</masterLabel>
            <translation><!-- Hematology --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Industry Professional</masterLabel>
            <translation><!-- Industry Professional --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Neurology</masterLabel>
            <translation><!-- Neurology --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Other</masterLabel>
            <translation><!-- Other --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Pharmacy</masterLabel>
            <translation><!-- Pharmacy --></translation>
        </picklistValues>
    </fields>
    <fields>
        <label>Intervenant de connaissance médicale</label>
        <name>Medical_Insight_Stakeholder_BMS__c</name>
        <picklistValues>
            <masterLabel>Business Development</masterLabel>
            <translation><!-- Business Development --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>HEOR</masterLabel>
            <translation><!-- HEOR --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Market Access / Managed Market</masterLabel>
            <translation><!-- Market Access / Managed Market --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Medical Strategy</masterLabel>
            <translation><!-- Medical Strategy --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Research and Development</masterLabel>
            <translation><!-- Research and Development --></translation>
        </picklistValues>
    </fields>
    <fields>
        <label><!-- Notes --></label>
        <name>Notes_BMS__c</name>
    </fields>
    <fields>
        <label>Autres sujets sur la connaissance clé</label>
        <name>Other_Key_Insight_Topics_BMS__c</name>
    </fields>
    <fields>
        <label>Autre Source Information Médicale</label>
        <name>Other_Medical_Insight_Source_Type_BMS__c</name>
    </fields>
    <fields>
        <label>Autre type de connaissance médicale</label>
        <name>Other_Type_of_Medical_Insight_BMS__c</name>
    </fields>
    <fields>
        <label>Produit</label>
        <name>Product_BMS_CAN__c</name>
        <picklistValues>
            <masterLabel>11βHSD Inhibitors</masterLabel>
            <translation><!-- 11βHSD Inhibitors --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>ABILIFY® (aripiprazole)</masterLabel>
            <translation><!-- ABILIFY® (aripiprazole) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>ATRIPLA® (efavirenz/emtricitabine/tenofovir disoproxil fumarate)</masterLabel>
            <translation><!-- ATRIPLA® (efavirenz/emtricitabine/tenofovir disoproxil fumarate) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>AVALIDE® (irbesartan hydrochlorothiazide)</masterLabel>
            <translation><!-- AVALIDE® (irbesartan hydrochlorothiazide) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>AVAPRO® (irbesartan)</masterLabel>
            <translation><!-- AVAPRO® (irbesartan) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Anti-CD28</masterLabel>
            <translation><!-- Anti-CD28 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Anti-CD40L</masterLabel>
            <translation><!-- Anti-CD40L --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Anti-CD70 ADC</masterLabel>
            <translation><!-- Anti-CD70 ADC --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Anti-CXCR4</masterLabel>
            <translation><!-- Anti-CXCR4 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Anti-IL31</masterLabel>
            <translation><!-- Anti-IL31 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Anti-IL6</masterLabel>
            <translation><!-- Anti-IL6 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Anti-IP10</masterLabel>
            <translation><!-- Anti-IP10 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Anti-KIR</masterLabel>
            <translation><!-- Anti-KIR --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Anti-LAG3</masterLabel>
            <translation><!-- Anti-LAG3 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Anti-PD-L1</masterLabel>
            <translation><!-- Anti-PD-L1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Anti-PD1</masterLabel>
            <translation><!-- Anti-PD1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Asunaprevir (NS3 Inhibitor)</masterLabel>
            <translation><!-- Asunaprevir (NS3 Inhibitor) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Avagacestat (Gamma Secretase Inhibitor)</masterLabel>
            <translation><!-- Avagacestat (Gamma Secretase Inhibitor) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Aβ Modulator</masterLabel>
            <translation><!-- Aβ Modulator --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>BARACLUDE® (entecavir)</masterLabel>
            <translation><!-- BARACLUDE® (entecavir) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>BICNU® (carmustine)</masterLabel>
            <translation><!-- BICNU® (carmustine) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>BUSPAR® (buspirone hydrochloride)</masterLabel>
            <translation><!-- BUSPAR® (buspirone hydrochloride) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Brivanib</masterLabel>
            <translation><!-- Brivanib --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CCR1 Antagonists</masterLabel>
            <translation><!-- CCR1 Antagonists --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CCR2 / 5</masterLabel>
            <translation><!-- CCR2 / 5 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CEENU® (lomustine)</masterLabel>
            <translation><!-- CEENU® (lomustine) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CGRP Antagonist</masterLabel>
            <translation><!-- CGRP Antagonist --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>COUMADIN® (warfarin sodium)</masterLabel>
            <translation><!-- COUMADIN® (warfarin sodium) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CVMet General</masterLabel>
            <translation><!-- CVMet General --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>DROXIA® (hydroxyurea)</masterLabel>
            <translation><!-- DROXIA® (hydroxyurea) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Daclatasvir (NS5A inhibitor)</masterLabel>
            <translation><!-- Daclatasvir (NS5A inhibitor) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>EGFR/IGFR Tandem Adnectin</masterLabel>
            <translation><!-- EGFR/IGFR Tandem Adnectin --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>ERBITUX® (cetuximab)</masterLabel>
            <translation><!-- ERBITUX® (cetuximab) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>ETOPOPHOS® (etoposide phosphate)</masterLabel>
            <translation><!-- ETOPOPHOS® (etoposide phosphate) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Eliquis®  (apixaban)</masterLabel>
            <translation><!-- Eliquis®  (apixaban) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Elotuzumab</masterLabel>
            <translation><!-- Elotuzumab --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>FGF21-PKE Adnectin</masterLabel>
            <translation><!-- FGF21-PKE Adnectin --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>FORXIGA® (dapagliflozin)</masterLabel>
            <translation><!-- FORXIGA® (dapagliflozin) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>GABA/Nicotinic Modulator</masterLabel>
            <translation><!-- GABA/Nicotinic Modulator --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>GLUCOPHAGE® (metformin hydrochloride)</masterLabel>
            <translation><!-- GLUCOPHAGE® (metformin hydrochloride) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>GPR119 Agonists</masterLabel>
            <translation><!-- GPR119 Agonists --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>HIV Attachment Inhibitor</masterLabel>
            <translation><!-- HIV Attachment Inhibitor --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>HIV General</masterLabel>
            <translation><!-- HIV General --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>HIV Maturation Inhibitor</masterLabel>
            <translation><!-- HIV Maturation Inhibitor --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>HYDREA® (hydroxyurea)</masterLabel>
            <translation><!-- HYDREA® (hydroxyurea) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Hepatitis General</masterLabel>
            <translation><!-- Hepatitis General --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>IGF-1R Antagonist</masterLabel>
            <translation><!-- IGF-1R Antagonist --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>IKACh Inhibitors</masterLabel>
            <translation><!-- IKACh Inhibitors --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>IKur</masterLabel>
            <translation><!-- IKur --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>IL-21</masterLabel>
            <translation><!-- IL-21 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>IL-23 Adnectin</masterLabel>
            <translation><!-- IL-23 Adnectin --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>IMS General</masterLabel>
            <translation><!-- IMS General --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>IXEMPRA® (ixabepilone)</masterLabel>
            <translation><!-- IXEMPRA® (ixabepilone) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>JAK2 Inhibitor</masterLabel>
            <translation><!-- JAK2 Inhibitor --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>KOMBIGLYZE™ XR (saxagliptin and metformin HCl extended-release)</masterLabel>
            <translation><!-- KOMBIGLYZE™ XR (saxagliptin and metformin HCl extended-release) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>LPA1 Antagonist</masterLabel>
            <translation><!-- LPA1 Antagonist --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>LXR Modulators</masterLabel>
            <translation><!-- LXR Modulators --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Mature Brands General</masterLabel>
            <translation><!-- Mature Brands General --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Microtubule Stabilizer</masterLabel>
            <translation><!-- Microtubule Stabilizer --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>NRT Inhibitor</masterLabel>
            <translation><!-- NRT Inhibitor --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>NS General</masterLabel>
            <translation><!-- NS General --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>NS5A Second Generation</masterLabel>
            <translation><!-- NS5A Second Generation --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>NS5B Inhibitor</masterLabel>
            <translation><!-- NS5B Inhibitor --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>NS5B Primer Grip Inhibitor</masterLabel>
            <translation><!-- NS5B Primer Grip Inhibitor --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>NS5B Site 1 Inhibitor</masterLabel>
            <translation><!-- NS5B Site 1 Inhibitor --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>NULOJIX® (belatacept)</masterLabel>
            <translation><!-- NULOJIX® (belatacept) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Necitumumab</masterLabel>
            <translation><!-- Necitumumab --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Notch Inhibitors</masterLabel>
            <translation><!-- Notch Inhibitors --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>ONGLYZA® (saxagliptin)</masterLabel>
            <translation><!-- ONGLYZA® (saxagliptin) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>ORENCIA® (abatacept)</masterLabel>
            <translation><!-- ORENCIA® (abatacept) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Oncology General</masterLabel>
            <translation><!-- Oncology General --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>PCSK9 Adnectin</masterLabel>
            <translation><!-- PCSK9 Adnectin --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>PEG-FGF21</masterLabel>
            <translation><!-- PEG-FGF21 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>PLAVIX® (clopidogrel bisulfate)</masterLabel>
            <translation><!-- PLAVIX® (clopidogrel bisulfate) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>PRAVACHOL® (pravastatin sodium)</masterLabel>
            <translation><!-- PRAVACHOL® (pravastatin sodium) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Pegdinetanib (VEGF R-2 Adnectin)</masterLabel>
            <translation><!-- Pegdinetanib (VEGF R-2 Adnectin) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Peginterferon lambda-1a</masterLabel>
            <translation><!-- Peginterferon lambda-1a --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>RECOTHROM® Thrombin, topical (recombinant)</masterLabel>
            <translation><!-- RECOTHROM® Thrombin, topical (recombinant) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>REYATAZ® (atazanavir sulfate)</masterLabel>
            <translation><!-- REYATAZ® (atazanavir sulfate) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>SMO Antagonist</masterLabel>
            <translation><!-- SMO Antagonist --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>SPRYCEL® (dasatinib)</masterLabel>
            <translation><!-- SPRYCEL® (dasatinib) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>SUSTIVA® (efavirenz)</masterLabel>
            <translation><!-- SUSTIVA® (efavirenz) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>TAXOL® (paclitaxel)</masterLabel>
            <translation><!-- TAXOL® (paclitaxel) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>TGR5 agonist</masterLabel>
            <translation><!-- TGR5 agonist --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Tempra IV® (paracetamol)</masterLabel>
            <translation><!-- Tempra IV® (paracetamol) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Triple Reuptake Inhibitors</masterLabel>
            <translation><!-- Triple Reuptake Inhibitors --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Urelumab (Anti-CD137)</masterLabel>
            <translation><!-- Urelumab (Anti-CD137) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>VIDEX® (didanosine)</masterLabel>
            <translation><!-- VIDEX® (didanosine) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>YERVOY™ (ipilimumab)</masterLabel>
            <translation><!-- YERVOY™ (ipilimumab) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>α-7 Nicotinic Agonist</masterLabel>
            <translation><!-- α-7 Nicotinic Agonist --></translation>
        </picklistValues>
    </fields>
    <fields>
        <label><!-- Region --></label>
        <name>Region__c</name>
    </fields>
    <fields>
        <label><!-- Sphere of Influence --></label>
        <name>Sphere_of_Influence_BMS__c</name>
        <picklistValues>
            <masterLabel>Clinical Trial Support</masterLabel>
            <translation><!-- Clinical Trial Support --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>HCP</masterLabel>
            <translation><!-- HCP --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Medical Strategy</masterLabel>
            <translation><!-- Medical Strategy --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>National</masterLabel>
            <translation><!-- National --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Payer/Government/Advocacy</masterLabel>
            <translation><!-- Payer/Government/Advocacy --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Regional</masterLabel>
            <translation><!-- Regional --></translation>
        </picklistValues>
    </fields>
    <fields>
        <label><!-- Status --></label>
        <name>Status_BMS_EMEA__c</name>
        <picklistValues>
            <masterLabel>Approved</masterLabel>
            <translation><!-- Approved --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Rejected</masterLabel>
            <translation><!-- Rejected --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Saved</masterLabel>
            <translation><!-- Saved --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Submitted - Pending Approval</masterLabel>
            <translation><!-- Submitted - Pending Approval --></translation>
        </picklistValues>
    </fields>
    <fields>
        <label>Secteur Thérapeutique</label>
        <name>Therapeutic_Area_BMS_IC__c</name>
        <picklistValues>
            <masterLabel>CVMet</masterLabel>
            <translation><!-- CVMet --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>IMS</masterLabel>
            <translation><!-- IMS --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Mature Brands</masterLabel>
            <translation><!-- Mature Brands --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>NS</masterLabel>
            <translation><!-- NS --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Oncology</masterLabel>
            <translation><!-- Oncology --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Virology</masterLabel>
            <translation><!-- Virology --></translation>
        </picklistValues>
    </fields>
    <fields>
        <label>Secteur Thérapeutique</label>
        <name>Therapeutic_Area_BMS__c</name>
        <picklistValues>
            <masterLabel>CV</masterLabel>
            <translation><!-- CV --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>IMS</masterLabel>
            <translation><!-- IMS --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>MET</masterLabel>
            <translation><!-- MET --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>NS</masterLabel>
            <translation><!-- NS --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Onc</masterLabel>
            <translation><!-- Onc --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Vr</masterLabel>
            <translation><!-- Vr --></translation>
        </picklistValues>
    </fields>
    <fields>
        <label>Type de connaissance médicale</label>
        <name>Type_of_Medical_Insight_BMS_IC__c</name>
        <picklistValues>
            <masterLabel>Access</masterLabel>
            <translation><!-- Access --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Clinical trial - Investigational compound</masterLabel>
            <translation><!-- Clinical trial - Investigational compound --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Clinical trial - Marketed brand</masterLabel>
            <translation><!-- Clinical trial - Marketed brand --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Common Practice / Treatment Patterns</masterLabel>
            <translation><!-- Common Practice / Treatment Patterns --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Competitive Landscape</masterLabel>
            <translation><!-- Competitive Landscape --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Disease State</masterLabel>
            <translation><!-- Disease State --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Industry News / Sales / Promotions</masterLabel>
            <translation><!-- Industry News / Sales / Promotions --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Medical Education</masterLabel>
            <translation><!-- Medical Education --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Other (Please Specify)</masterLabel>
            <translation><!-- Other (Please Specify) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Outcomes / Pharmacoeconomics</masterLabel>
            <translation><!-- Outcomes / Pharmacoeconomics --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Product Perception</masterLabel>
            <translation><!-- Product Perception --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Regulatory/Filings</masterLabel>
            <translation><!-- Regulatory/Filings --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Unmet Medical Need</masterLabel>
            <translation><!-- Unmet Medical Need --></translation>
        </picklistValues>
    </fields>
    <fields>
        <label>Type de connaissance médicale</label>
        <name>Type_of_Medical_Insight_BMS__c</name>
        <picklistValues>
            <masterLabel>Access</masterLabel>
            <translation><!-- Access --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Clinical Trial: Investigational Compound</masterLabel>
            <translation><!-- Clinical Trial: Investigational Compound --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Clinical Trial: Marked Brand</masterLabel>
            <translation><!-- Clinical Trial: Marked Brand --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Common Practice / Treatment Patterns</masterLabel>
            <translation><!-- Common Practice / Treatment Patterns --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Competitive Landscape</masterLabel>
            <translation><!-- Competitive Landscape --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Disease State</masterLabel>
            <translation><!-- Disease State --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Industry News / Sales / Promotions</masterLabel>
            <translation><!-- Industry News / Sales / Promotions --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Medical Education</masterLabel>
            <translation><!-- Medical Education --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Other</masterLabel>
            <translation><!-- Other --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Outcomes</masterLabel>
            <translation><!-- Outcomes --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Product Perception</masterLabel>
            <translation><!-- Product Perception --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Regulatory / Filings</masterLabel>
            <translation><!-- Regulatory / Filings --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Unmet Medical Need</masterLabel>
            <translation><!-- Unmet Medical Need --></translation>
        </picklistValues>
    </fields>
    <gender>Masculine</gender>
    <nameFieldLabel><!-- Field Medical Insights Name --></nameFieldLabel>
    <recordTypes>
        <label><!-- BMS - EMEA - FMI --></label>
        <name>BMS_EMEA_FMI</name>
    </recordTypes>
    <recordTypes>
        <label><!-- BMS-Intercon-SA-FMI --></label>
        <name>BMS_Intercon_SA_FMI</name>
    </recordTypes>
    <recordTypes>
        <label><!-- BMS-US-FMI --></label>
        <name>BMS_US_FMI</name>
    </recordTypes>
    <startsWith>Consonant</startsWith>
</CustomObjectTranslation>
